Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Biogen Appoints EVP, CCO | Contract Pharma

What are you searching for?

Sign in
Promotions & Moves

Biogen Appoints EVP, CCO

Merck veteran to lead commercial strategy

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Michel Vounatsos has been appointed executive vice president and chief commercial officer at Biogen, effective April 18, 2016.
 
Mr. Vounatsos will oversee the development and execution of Biogen’s global commercial strategy, with a focus on the company’s product portfolio and the development of the commercial infrastructure to support key pipeline assets. He will report to George Scangos, Ph.D., chief executive officer, and will be a member of the management team.
 
Mr. Vounatsos joins the company from Merck, where he spent 20 years, most recently as president, Primary Care Business Line and Merck Customer Centricity. Prior to this role, he held leadership positions at Merck across Europe and in China.
 
“Michel is a sophisticated global business leader who brings a track record of commercial success and creativity to Biogen,” said Dr. Scangos. “As the complexity of our business and the expectations of our stakeholders accelerate, Michel will play a critical role in driving our near-term growth while helping prepare our organization to support our increasingly robust and diverse pipeline.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters